Alaunos Therapeutics (NASDAQ:TCRT) Shares Set to Reverse Split on Thursday, July 18th

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s stock is set to reverse split on the morning of Thursday, July 18th. The 1-10 reverse split was announced on Thursday, July 18th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, July 18th.

Alaunos Therapeutics Stock Down 9.3 %

Shares of TCRT traded down $0.06 during trading hours on Tuesday, reaching $0.61. 197,967 shares of the company traded hands, compared to its average volume of 129,182. The stock’s fifty day moving average is $0.94 and its 200 day moving average is $1.51. Alaunos Therapeutics has a 1-year low of $0.56 and a 1-year high of $7.50.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. Virtu Financial LLC bought a new position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 15,440 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned 0.10% of Alaunos Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 27.72% of the company’s stock.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.